Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 11/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8738221 | 0.92 | EZH2 (0.80) | EZH2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL8738237 | 0.91 | EZH2 (0.81) | EZH2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL8738695 | 0.90 | EZH2 (0.91) | EZH2SLC2A1 | |
| SCHEMBL8738997 | 0.90 | EZH2 (1.00) | EZH2MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17067308 | 0.89 | EZH2 (0.74) | EZH2ATML3MBTL1MEN1KMT2A | |
| SCHEMBL8738594 | 0.88 | EZH2 (0.77) | EZH2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL8738264 | 0.88 | EZH2 (0.77) | EZH2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL8739028 | 0.88 | EZH2 (0.80) | EZH2ATML3MBTL1MAPTMEN1 | |
| SCHEMBL8738136 | 0.87 | EZH2 (0.75) | EZH2L3MBTL1MAPTALDH1A1MEN1 | |
| SCHEMBL8738308 | 0.86 | EZH2 (0.73) | EZH2ATML3MBTL1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | EZH2 61/4885ATM 1850/4885L3MBTL1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.